Abstract
INTRODUCTION: Glucagon-like peptide-1 receptor agonists such as liraglutide have revolutionized the management of type 2 diabetes and obesity. CASE PRESENTATION: We present a case of a 30-year-old woman who developed drug-induced liver injury (DILI) to liraglutide, confirmed on histology, with resolution on cessation of liraglutide over 6 months. CONCLUSION: DILI secondary to liraglutide appears to be a rare but an important adverse effect.